Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.

अन्य संस्करण दिखाएं (1)

BACKGROUND: We are developing a heterologous prime-boost vaccine strategy against malaria. This approach uses sequential immunization with different vectors to deliver a common preerythrocytic malaria antigen. Preliminary evidence of efficacy and safety has been previously documented in studies fro...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Bejon, P, Peshu, N, Gilbert, S, Lowe, B, Molyneux, C, Forsdyke, J, Lang, T, Hill, A, Marsh, K
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	2006

समान संसाधन

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2006)

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2006)

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2006)

Safety and immunogenicity of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP in semi-immune adult males [MIM-OK-87312]
द्वारा: Kai, O, और अन्य
प्रकाशित: (2005)

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
द्वारा: Webster, D, और अन्य
प्रकाशित: (2006)

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2007)

Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2007)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
द्वारा: Walther, M, और अन्य
प्रकाशित: (2006)

Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908]
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2005)

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
द्वारा: Philip Bejon, और अन्य
प्रकाशित: (2007-08-01)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
द्वारा: Webster, D, और अन्य
प्रकाशित: (2005)

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
द्वारा: Dunachie, S, और अन्य
प्रकाशित: (2006)

Clinical development of Modified Vaccinia virus Ankara vaccines.
द्वारा: Gilbert, S
प्रकाशित: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
द्वारा: Gilbert, S
प्रकाशित: (2013)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
द्वारा: Rampling, T, और अन्य
प्रकाशित: (2016)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
द्वारा: Hodgson, SH, और अन्य
प्रकाशित: (2014)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
द्वारा: Caroline Staib, और अन्य
प्रकाशित: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
द्वारा: Olga Vladimirovna Orlova, और अन्य
प्रकाशित: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
द्वारा: Volker Sandig, और अन्य
प्रकाशित: (2013-11-01)

The Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites as a candidate for preerythrocytic and transmission-blocking vaccines.
द्वारा: Espinosa, D, और अन्य
प्रकाशित: (2016)

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
द्वारा: Alves, E, और अन्य
प्रकाशित: (2017)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
द्वारा: Hodgson, S, और अन्य
प्रकाशित: (2014)

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.
द्वारा: Bejon, P, और अन्य
प्रकाशित: (2005)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
द्वारा: C. Staib, और अन्य
प्रकाशित: (2000-06-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
द्वारा: Mingwang Shen, और अन्य
प्रकाशित: (2024-10-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
द्वारा: Kaïdre Bendjama, और अन्य
प्रकाशित: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
द्वारा: Malachy I. Okeke, और अन्य
प्रकाशित: (2017-10-01)

Enhanced Expression of the <i>L1R</i> Gene of Vaccinia Virus by the tPA Signal Sequence Inserted in a Fowlpox-Based Recombinant Vaccine
द्वारा: Antonia Radaelli, और अन्य
प्रकाशित: (2024-09-01)

IMMUNOBIOLOGICAL PROPERTIES OF FOWLPOX VIRUS CULTURAL VARIANTS
द्वारा: K. Yu. Fedoseyev, और अन्य
प्रकाशित: (2018-04-01)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children
द्वारा: Olotu, A, और अन्य
प्रकाशित: (2014)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.
द्वारा: Ally Olotu, और अन्य
प्रकाशित: (2014-01-01)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
द्वारा: Smith, C, और अन्य
प्रकाशित: (2005)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
द्वारा: Dorrell, L, और अन्य
प्रकाशित: (2000)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
द्वारा: Moorthy, V, और अन्य
प्रकाशित: (2003)

A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection
द्वारा: Mareike Kubinski, और अन्य
प्रकाशित: (2023-04-01)

Construction of Deletion-knockout Mutant Fowlpox Virus (FWPV)
द्वारा: Stephen Laidlaw, और अन्य
प्रकाशित: (2014-05-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
द्वारा: López-Camacho, C, और अन्य
प्रकाशित: (2019)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
द्वारा: Gilbert, S, और अन्य
प्रकाशित: (1999)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
द्वारा: Alharbi, N
प्रकाशित: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
द्वारा: César López-Camacho, और अन्य
प्रकाशित: (2019-11-01)